Antifungal use via outpatient parenteral antimicrobial therapy

S.M. Chew; C.H. Heath; C. Petursson; P.A. Boan; J.O. Robinson; C.M. Italiano; J.R. Dyer; L. Manning; P.R. Ingram

doi:10.1111/myc.13513

Back

Antifungal use via outpatient parenteral antimicrobial therapy

Journal article

Peer reviewed

Antifungal use via outpatient parenteral antimicrobial therapy

S.M. Chew, C.H. Heath, C. Petursson, P.A. Boan, J.O. Robinson, C.M. Italiano, J.R. Dyer, L. Manning and P.R. Ingram

Mycoses, Vol.65(10), pp.946-952

2022

DOI: https://doi.org/10.1111/myc.13513

Files and links (1)

url

Link to Published Version *Subscription may be requiredView

Abstract

Background Antifungal administration via outpatient parenteral antimicrobial therapy (OPAT) is infrequent. As patients with invasive fungal infections (IFIs) receiving OPAT are at high risk of readmissions, careful, risk-based patient selection and monitoring is important. Objectives To describe our experience managing IFIs via OPAT, including assessment of risk factors associated with unplanned readmissions. Patients and Methods A retrospective cohort study of outpatients from two tertiary hospitals in Western Australia managed with parenteral antifungals for the treatment of IFIs from 2012 to 2020. Outcomes assessed were unplanned OPAT-related readmissions; adverse events and achievement of treatment aim at the completion of OPAT. Results Forty-six patients were included, encompassing 696 OPAT days. Twenty-three (50%) patients received intravenous (IV) liposomal amphotericin B (L-AmB), 23 (50%) received IV echinocandins and one (2%) patient received IV fluconazole. One patient received both IV L-AmB and an echinocandin. Unplanned OPAT-related readmissions occurred in 13 (28%) patients and any adverse event occurred in 19 (41%), most commonly nephrotoxicity amongst patients receiving L-AmB. On univariate analysis, unplanned OPAT-related readmissions were more common in Mucorales infection, L-AmB doses of ≥5 mg/kg and otorhinolaryngologic (ENT) infections. At the completion of OPAT, attainment of treatment aims occurred in 28 (61%) patients. Conclusions Patients receiving parenteral antifungals via OPAT experience high rates of unplanned readmissions and adverse events. Risk factor identification may facilitate optimal patient selection and establishment of treatment aims.

Details

Title: Antifungal use via outpatient parenteral antimicrobial therapy
Authors/Creators: S.M. Chew (Author/Creator) - Fiona Stanley Hospital
C.H. Heath (Author/Creator) - Royal Perth Hospital
C. Petursson (Author/Creator) - Royal Perth Hospital
P.A. Boan (Author/Creator) - Royal Perth Hospital
J.O. Robinson (Author/Creator) - Fiona Stanley Hospital
C.M. Italiano (Author/Creator) - Royal Perth Hospital
J.R. Dyer (Author/Creator) - Fiona Stanley Hospital
L. Manning (Author/Creator) - Fiona Stanley Hospital
P.R. Ingram (Author/Creator) - Fiona Stanley Hospital
Publication Details: Mycoses, Vol.65(10), pp.946-952
Publisher: Blackwell Publishing
Identifiers: 991005541911407891
Copyright: © 2022 Wiley-VCH GmbH
Murdoch Affiliation: Antimicrobial Resistance and Infectious Disease Laboratory; School of Veterinary and Life Sciences
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

95 Record Views

5 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.148 Medical Mycology; 1.148.94 Antifungal Strategies
Web Of Science research areas: Dermatology; Mycology
ESI research areas: Plant & Animal Science